US EditionPublished • loading... • Updated
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability to substantially reduce antiAAV antibodies to allow administration of gene therapy. Lund, Sweden, 30 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report for January-September 2025. Read more… The post Hansa Biopharma Reports Third Quarter an…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
